Welcome to our dedicated page for Tandem Diabetes Care news (Ticker: $TNDM), a resource for investors and traders seeking the latest updates and insights on Tandem Diabetes Care stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tandem Diabetes Care's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tandem Diabetes Care's position in the market.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) reported a 13% increase in worldwide GAAP sales to $191.7 million and a 12% increase in non-GAAP sales to $192.8 million for the first quarter of 2024. The company launched Tandem Mobi with Dexcom G6 CGM sensor integration and t:slim X2 with Abbott Freestyle Libre 2 Plus CGM sensor integration in the US, among other initiatives. The increase in pump shipments and financial results showcased positive growth. However, the company reported a net loss for the quarter.
Tandem Diabetes Care, Inc. (TNDM) will present at investor conferences on May 15 and May 29, 2024, providing company updates. The presentations will be webcast live and archived for 30 days.